Literature DB >> 11790688

Eligibility for lipid-lowering drug therapy in primary prevention: how do the Adult Treatment Panel II and Adult Treatment Panel III Guidelines compare?

Antonio M Gotto, Lewis H Kuller.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11790688

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  4 in total

1.  Simvastatin overcomes the resistance to serum withdrawal-induced apoptosis of lymphocytes from Alzheimer's disease patients.

Authors:  Fernando Bartolomé; Ursula Muñoz; Noemí Esteras; Carolina Alquezar; Andrea Collado; Félix Bermejo-Pareja; Angeles Martín-Requero
Journal:  Cell Mol Life Sci       Date:  2010-07-08       Impact factor: 9.261

Review 2.  Beyond lipid-lowering: effects of statins on endothelial nitric oxide.

Authors:  Ulrich Laufs
Journal:  Eur J Clin Pharmacol       Date:  2003-02-18       Impact factor: 2.953

3.  Altered profile of circulating endothelial progenitor cells in obstructive sleep apnea.

Authors:  Macy Mei-Sze Lui; Hung-Fat Tse; Judith Choi-Wo Mak; Jamie Chung-Mei Lam; David Chi-Leung Lam; Kathryn C B Tan; Mary Sau-Man Ip
Journal:  Sleep Breath       Date:  2012-11-21       Impact factor: 2.816

4.  Retrospective analysis of the safety and efficacy of high-dose interleukin-2 after prior tyrosine kinase inhibitor therapy in patients with advanced renal cell carcinoma.

Authors:  Elaine T Lam; Michael K K Wong; Neeraj Agarwal; Bruce G Redman; Theodore Logan; Dexiang Gao; Thomas W Flaig; Karl Lewis; Jamie Poust; Paul Monk; Anthony Jarkowski; Arun Sendilnathan; Marcus Bolden; Timothy M Kuzel; Thomas Olencki
Journal:  J Immunother       Date:  2014-09       Impact factor: 4.456

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.